scorecardresearch
Add as a preferred source on Google
Monday, January 26, 2026
TopicEli Lilly

Topic: Eli Lilly

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Eli Lilly announces trial results for world’s 2nd weekly insulin, aims for launch by year-end

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on...

Fat-busting drug Mounjaro launched in India. Here’s how much it will cost

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, it has since become a global blockbuster.

Ozempic on steroids? Successor that could cut down weight in half the time coming soon

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.

Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year

Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.

Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price

Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.

Has a ‘magical’ weight loss drug finally arrived? Hopes soar with US firm’s never-before-seen results

Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.

WHO approves Glaxo and Eli Lilly drugs to treat Covid amid Omicron surge

Eli Lilly’s rheumatoid arthritis drug and GlaxoSmithKline's monoclonal antibody won the WHO nod.

Blocked by Eli Lilly, Bajaj Healthcare moves patent office to make Covid drug Baricitinib

BHL says it can produce Baricitinib for as cheap as Rs 14 (for 1mg). US pharma giant Eli Lilly, which holds exclusive licence for the drug, manufactures it at an average cost of Rs 3,230.

On Camera

Rahul Gandhi should be more worried about Amit Shah the cooperation minister—than home minister

The cooperation ministry is working on a war footing. Even if cooperative societies are in the state list, the Centre is doing its best to streamline and reinvigorate the sector.

India wants Canada’s resources as nations build on truce, British Columbia’s Premier says

Premier David Eby, the leader of the minerals- and gas-rich province of British Columbia, spoke with executives at Tata Steel and Reliance Industries on a trade mission to India.

From action near Myanmar to hand-to-hand combat in Kishtwar, meet this year’s gallantry award winners

Overall, President Droupadi Murmu has approved Gallantry awards to 70 armed forces personnel, including six posthumous, on the eve of 77th Republic Day.

Non-alignment is coming back in a new avatar: Trump-peedit alliance

No nation other than China can negotiate one-on-one with Trump on an equal footing. That’s why the middle powers who so far formed the core of multilateral bodies now feel orphaned.